GAS6 and leukemia: Remarkably, sh-GAS6-AS1 extended the survival of the recipients from 26 days for sh-Scb–treated mice to 36 days for sh-GAS6-AS1–treated mice (Fig. 7G; P = 0.0050), suggesting that GAS6-AS1 knockdown inhibits leukemia progression.